SCHEMBL417132

SCHEMBL417132

NC(=O)c1csc(C2CCNCC2)n1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.47
BAZ2A Q9UIF9 2/20 0.44
GSK3B P49841 1/20 0.42
DYRK1A Q13627 1/20 0.42
HPGDS O60760 1/20 0.42
PARP1 P09874 5/20 0.40
CDC7 O00311 1/20 0.39
SPR P35270 2/20 0.39
HTR2B P41595 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
JAK2 O60674 2/20 0.38
JAK1 P23458 2/20 0.38
TYK2 P29597 2/20 0.38
JAK3 P52333 2/20 0.38
PIM1 P11309 1/20 0.36
PIM3 Q86V86 1/20 0.36
PIM2 Q9P1W9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylene Chloride SCHEMBL27709754 0.94 AOC3 (0.46) AOC3BAZ2AGSK3BDYRK1AHPGDS
SCHEMBL12467241 0.89 HTR2B (0.42) AOC3SPRHTR2BPIM1PIM3
SCHEMBL491211 0.86 HPGDS (0.46) AOC3BAZ2AGSK3BDYRK1AHPGDS
SCHEMBL13997973 0.84 BAZ2A (0.52) AOC3BAZ2AGSK3BDYRK1AHPGDS
SCHEMBL28264041 0.84 PIM1 (0.46) CDC7SPRHTR2BMEN1KMT2A
SCHEMBL2554941 0.84 PIM1 (0.46) CDC7SPRHTR2BMEN1KMT2A
Hydrochloric Acid SCHEMBL2516985 0.83 BAZ2A (0.51) AOC3BAZ2AGSK3BDYRK1AHPGDS
SCHEMBL26979851 0.81 HTR2B (0.38) SPRHTR2BPIM1PIM3PIM2
SCHEMBL14379269 0.81 PLAT (0.45) AOC3BAZ2AGSK3BDYRK1AHPGDS
SCHEMBL31705780 0.81 PLAT (0.45) AOC3BAZ2AGSK3BDYRK1AHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111196805-A Synthesis method and application of piperidyl thiazole formamide compound 曲阜德禄生物科技有限公司 2020-05-26 CN claimed
CN-111196805-A Synthesis method and application of piperidyl thiazole formamide compound 曲阜德禄生物科技有限公司 2020-05-26 CN disclosed
CN-111196805-A Synthesis method and application of piperidyl thiazole formamide compound 曲阜德禄生物科技有限公司 2020-05-26 CN disclosed
CN-105744833-B Use the fluidized bed prilling of Prohexadione calcium and the aqueous solution of mineral sulfates 巴斯夫欧洲公司 2018-07-24 CN disclosed
CN-103561570-B Alkoxylated polyalkyleneimine as agrochemical formula dispersant 巴斯夫欧洲公司 2016-10-05 CN disclosed
CN-104378980-B Comprise the emulsifiable concentrate of pesticide, amide, carbonic ester and hydrocarbon 巴斯夫欧洲公司 2016-08-24 CN disclosed
CN-102596910-A Androgen receptor modulating compounds ORION CORP 2012-07-18 CN disclosed
US-8106048-B2 protozoal infestations in humans and animals, by bacteria, viruses or proteinaceous agents; neurological diseases or disorders; ischemia and/or reperfusion injury; 4-(4-Ethoxycarbonyl-4,5-dihydro-thiazol-2-yl)-piperidine-1-carboxylic acid t-butyl ester 4SC AG (DE) 2012-01-31 US disclosed
US-20120022068-A1 NOVEL HETEROCYCLIC NF-kB INHIBITORS 4SC AG (DE) 2012-01-26 US disclosed
EP-2343293-A1 NOVEL PIPERIDIN-4-YL-THIAZOLE-CARBOXAMIDE ANALOGUES AS INHIBITORS OF T-CELL PROLIFERATION AND USES THEREOF 4SC AG (DE) 2011-07-13 EP disclosed
WO-2007104557-A2 NOVEL HETEROCYCLIC NF-KB INHIBITORS 4SC AG (DE) 2007-09-20 WO disclosed
WO-2007104558-A1 THIAZOLES AS NF-KB INHIBITORS (PROTEASOME INHIBITORS) 4SC AG (DE) 2007-09-20 WO disclosed
US-20070219190-A1 Heterocyclic NF-kB Inhibitors 4SC AG (DE) 2007-09-20 US disclosed
EP-1834954-A1 Thiazoles as NF-kB Inhibitors (proteasome inhibitors) 4SC AG (DE) 2007-09-19 EP disclosed
EP-1797084-A1 NOVEL HETEROCYCLIC NF-kB INHIBITORS 4SC AG (DE) 2007-06-20 EP disclosed
WO-2007016979-A2 NOVEL HETEROCYCLIC NF-κB INHIBITORS 4SC AG (DE) 2007-02-15 WO disclosed
US-20060247253-A1 Novel heterocyclic NF-kB inhibitors 4 SC AG (DE) 2006-11-02 US disclosed
WO-2006032322-A1 NOVEL HETEROCYCLIC NF-κB INHIBITORS 4SC AG (DE) 2006-03-30 WO disclosed
US-20060069102-A1 Novel heterocyclic NF-kB inhibitors 4 SC AG (DE) 2006-03-30 US disclosed
EP-1637529-A1 Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof 4SC AG (DE) 2006-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219190-A1 Heterocyclic NF-kB Inhibitors NFKBIA, NFKB2, NFRKB AOC3 1567/4885BAZ2A 1435/4885GSK3B 908/4885
US-20060247253-A1 Novel heterocyclic NF-kB inhibitors NFKBIA, NFRKB, NFKB2 AOC3 524/4885BAZ2A 778/4885GSK3B 1729/4885
US-20120022068-A1 NOVEL HETEROCYCLIC NF-kB INHIBITORS NFKB2, NFKBIA, NFRKB AOC3 1825/4885BAZ2A 337/4885GSK3B 1735/4885
US-20060069102-A1 Novel heterocyclic NF-kB inhibitors NFKBIA, NFKB2, NFRKB AOC3 1312/4885BAZ2A 1676/4885GSK3B 1642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.